Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Ovarian Neoplasms × cabazitaxel × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 22 Neoplasm Metastasis 7 Neoplasms 5 Prostate Cancer Metastatic 4 Carcinoma, Transitional Cell 4 Recurrence 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Carcinoma, Squamous Cell 2 Solid Cancer 1 Small Cell Lung Carcinoma 1 Penile Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Malignant Solid Tumor - Malignant Nervous System Neoplasm 1 Liposarcoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Bone Metastatic Prostate Cancer 1 Advanced Solid Tumor 1

Interventions

Carboplatin 160 Paclitaxel 153 Bevacizumab 65 Topotecan 49 liposomal doxorubicin 47 Gemcitabine 47 Cisplatin 40 Cyclophosphamide 35 Docetaxel 34 Filgrastim 27 pembrolizumab 26 Doxorubicin 26 olaparib 25 niraparib 19 Drug Therapy 19 Taxes 18 Peripheral Blood Stem Cell Transplantation 18 Etoposide 15 Nivolumab 14 veliparib 13 sargramostim 12 Surveys and Questionnaires 12 Trabectedin 11 Immunoglobulin G 11 Ifosfamide 11 Disulfides 11 Albumin-Bound Paclitaxel 11 pazopanib 10 durvalumab 10 atezolizumab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡